The UK has allowed Vertex Pharmaceuticals to use its Casgevy gene therapy for kids five and up.

Oct 30, 2026, 7:04 AM ETTrialRead the original at marketscreener.com

Good for VRTX

Vertex can now provide Casgevy to UK children aged 5 and older, expanding who may receive the treatment. The regulator will continue safety checks, but the report names no new safety concern.

VRTX · Vertex Pharmaceuticals

AI read · Good for VRTX

The AI's read

A younger eligible group gives Vertex a chance to reach more patients and broaden Casgevy's use. The regulator's review covered safety, quality, and effectiveness. Ongoing safety checks remain, but the report gives no new safety concern.

Get alerts for VRTX

Follow Vertex Pharmaceuticals (VRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRTX

Free on the App Store and Google Play, or on the web.